In cancer radiotherapy, gold nanoparticles (AuNPs) have emerged as promising radiosensitizers, which accumulate in the tumor and increase the effectiveness of external beam radiotherapy by local production of reactive
oxygen species (ROS) and secondary electrons upon irradiation. Five nm gold nanoparticles surrounded by an organic shell of polyallylamine (PAA) are produced by plasma vapor deposition and are conjugated to anti-EGFR-antibodies (Cetuximab-Ctxb) for active tumor targeting (AuNPs-PAA-Ctxb). In order to increase the therapeutic effect of the AuNPs-PAA-Ctxb, we aim to radiolabel the nanoparticles with 177Lu.
|Title of host publication||Annual Congress of the European Association of Nuclear Medicine October 12 – 16, 2019 Barcelona, Spain|
|Number of pages||1|
|State||Published - 31 Dec 2019|
|Name||European Journal of Nuclear Medicine and Molecular Imaging|